Molecular imaging of cellular immunotherapies in experimental and therapeutic settings.
Cell tracking
Imaging probes
Immunotherapies
Molecular imaging
Reporter genes
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
16
10
2020
accepted:
28
09
2021
pubmed:
18
10
2021
medline:
25
5
2022
entrez:
17
10
2021
Statut:
ppublish
Résumé
Cell-based cancer immunotherapies are becoming a routine part of the armamentarium against cancer. While remarkable successes have been seen, including durable remissions, not all patients will benefit from these therapies and many can suffer from life-threatening side effects. These differences in efficacy and safety across patients and across tumor types (e.g., blood vs. solid), are thought to be due to differences in how well the immune cells traffic to their target tissue (e.g., tumor, lymph nodes, etc.) whilst avoiding non-target tissues. Across patient variability can also stem from whether the cells interact with (i.e., communicate with) their intended target cells (e.g., cancer cells), as well as if they proliferate and survive long enough to yield potent and long-lasting therapeutic effects. However, many cell-based therapies are monitored by relatively simple blood tests that lack any spatial information and do not reflect how many immune cells have ended up at particular tissues. The ex vivo labeling and imaging of infused therapeutic immune cells can provide a more precise and dynamic understanding of whole-body immune cell biodistribution, expansion, viability, and activation status in individual patients. In recent years numerous cellular imaging technologies have been developed that may provide this much-needed information on immune cell fate. For this review, we summarize various ex vivo labeling and imaging approaches that allow for tracking of cellular immunotherapies for cancer. Our focus is on clinical imaging modalities and summarize the progression from experimental to therapeutic settings. The imaging information provided by these technologies can potentially be used for many purposes including improved real-time understanding of therapeutic efficacy and potential side effects in individual patients after cell infusion; the ability to more readily compare new therapeutic cell designs to current designs for various parameters such as improved trafficking to target tissues and avoidance of non-target tissues; and the long-term ability to identify patient populations that are likely to be positive responders and at low-risk of side effects.
Identifiants
pubmed: 34657195
doi: 10.1007/s00262-021-03073-5
pii: 10.1007/s00262-021-03073-5
pmc: PMC9122865
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1281-1294Informations de copyright
© 2021. The Author(s).
Références
Nucl Med Commun. 2006 Jan;27(1):25-30
pubmed: 16340720
Eur J Nucl Med. 2001 Jun;28(6):721-9
pubmed: 11440032
Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):842-8
pubmed: 20198473
Radiol Imaging Cancer. 2019 Nov 29;1(2):e190035
pubmed: 33778683
J Nucl Med. 2014 Apr;55(4):686-94
pubmed: 24604910
Biomed Opt Express. 2011 Mar 02;2(4):771-80
pubmed: 21483602
Theranostics. 2018 Nov 28;8(21):6070-6087
pubmed: 30613283
Front Med (Lausanne). 2020 Feb 14;7:34
pubmed: 32118018
Cancer Med. 2018 May;7(5):1860-1869
pubmed: 29601672
Nucl Med Biol. 2008 Jul;35(5):579-88
pubmed: 18589302
Nanotheranostics. 2018 Jun 1;2(3):258-268
pubmed: 29868350
Nucl Med Biol. 2002 Jan;29(1):13-8
pubmed: 11786271
Magn Reson Med. 2014 Dec;72(6):1696-701
pubmed: 25241945
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3030-5
pubmed: 11867752
Radiology. 2015 May;275(2):490-500
pubmed: 25706654
PLoS One. 2016 Oct 13;11(10):e0164557
pubmed: 27736925
Biomaterials. 2013 Jul;34(21):4926-35
pubmed: 23578557
Nat Biotechnol. 2005 Nov;23(11):1407-13
pubmed: 16258544
Mol Ther. 2020 Oct 7;28(10):2271-2285
pubmed: 32645298
Mol Imaging Biol. 2020 Jun;22(3):612-622
pubmed: 31385127
J Clin Endocrinol Metab. 2007 Nov;92(11):4451-8
pubmed: 17698909
CRISPR J. 2018 Dec;1:440-449
pubmed: 31021241
Mol Ther. 2019 Jan 2;27(1):219-229
pubmed: 30429045
Magn Reson Med. 2020 Mar;83(3):974-987
pubmed: 31631402
Nature. 2018 Jan 3;553(7686):86-90
pubmed: 29300010
Biotechnol Lett. 2017 Jul;39(7):1079-1089
pubmed: 28396958
RSC Adv. 2020 Nov 12;10(68):41305-41314
pubmed: 35516581
Cancer Res. 2003 Jan 1;63(1):12-7
pubmed: 12517769
Gene Ther. 2004 Jan;11(2):161-9
pubmed: 14712300
Radiology. 2015 Jan;274(1):192-200
pubmed: 25222066
Hum Gene Ther. 2015 Dec;26(12):813-25
pubmed: 26467629
PLoS One. 2018 Mar 7;13(3):e0193832
pubmed: 29513764
Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):835-41
pubmed: 20198474
Cancer Res. 2016 Jul 15;76(14):4113-23
pubmed: 27354381
MAGMA. 2014 Jun;27(3):219-26
pubmed: 24046072
Sci Adv. 2019 Jul 03;5(7):eaaw5096
pubmed: 31281894
Cancer Res. 1993 Dec 15;53(24):5867-71
pubmed: 8261395
Radiology. 2015 Jul;276(1):228-32
pubmed: 25942417
Small. 2018 Jan;14(3):
pubmed: 29168917
Shock. 2019 Oct;52(1S Suppl 1):60-64
pubmed: 29087985
Sci Transl Med. 2017 Jan 18;9(373):
pubmed: 28100832
J Biophotonics. 2018 Sep;11(9):e201800073
pubmed: 29701012
J Nucl Med. 2003 Nov;44(11):1827-38
pubmed: 14602867
Mol Imaging Biol. 2018 Oct;20(5):808-815
pubmed: 29508263
EJNMMI Res. 2017 Dec;7(1):32
pubmed: 28378292
J Immunother Cancer. 2016 May 17;4:27
pubmed: 27190628
Molecules. 2016 May 18;21(5):
pubmed: 27213309
Eur Radiol. 2005 Jan;15(1):4-13
pubmed: 15616814
Cancer Res. 2007 Dec 15;67(24):11959-69
pubmed: 18089827
J Clin Endocrinol Metab. 2002 Mar;87(3):1247-53
pubmed: 11889195
PLoS One. 2015 May 20;10(5):e0125291
pubmed: 25993535
Cancer Res. 2014 Sep 15;74(18):5173-83
pubmed: 25038231
Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):133-7
pubmed: 8278353
EJNMMI Res. 2020 Jul 14;10(1):82
pubmed: 32666311
Oncoimmunology. 2016 Feb 18;5(5):e1143996
pubmed: 27467963
NMR Biomed. 2013 Jul;26(7):860-71
pubmed: 23606473
Mol Imaging Biol. 2020 Jun;22(3):549-561
pubmed: 31286351
Radiology. 2015 Jun;275(3):772-82
pubmed: 25742194
J Nucl Med. 2002 Aug;43(8):1072-83
pubmed: 12163634
Cancer Biol Med. 2019 Nov;16(4):756-770
pubmed: 31908893
J Nucl Med. 2018 Oct;59(10):1531-1537
pubmed: 29728514
Nanotheranostics. 2021 Apr 27;5(4):431-444
pubmed: 33972919
Sci Rep. 2017 Apr 19;7(1):946
pubmed: 28424464
J Transl Med. 2004 Jul 30;2(1):27
pubmed: 15285807
Cancer Res. 1998 Oct 1;58(19):4333-41
pubmed: 9766661
Biomed Res Int. 2014;2014:203601
pubmed: 24991539
Magn Reson Med. 2018 Jul;80(1):304-316
pubmed: 29193231
Eur J Nucl Med. 1997 May;24(5):497-504
pubmed: 9142729
Magn Reson Insights. 2015 Oct 06;8(Suppl 1):15-29
pubmed: 26483609
Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1547-60
pubmed: 14579096
Nat Med. 1996 Feb;2(2):216-23
pubmed: 8574968
Nat Commun. 2018 Mar 14;9(1):1081
pubmed: 29540684
Br J Cancer. 2011 Sep 6;105(6):778-86
pubmed: 21847128
J Transl Med. 2006 Nov 14;4:49
pubmed: 17105663
Nanoscale. 2013 Dec 7;5(23):11409-15
pubmed: 23838997
Magn Reson Med. 2006 Feb;55(2):242-9
pubmed: 16416426
Magn Reson Med. 2018 Feb;79(2):1010-1019
pubmed: 28480589
J Neurooncol. 2019 May;142(3):395-407
pubmed: 30788681
Sci Rep. 2015 Sep 11;5:14055
pubmed: 26358296
Sci Adv. 2021 Jan 20;7(4):
pubmed: 33523917
Invest Radiol. 2019 May;54(5):302-311
pubmed: 30672844